围术期核因子-κB抑制剂FUT-175预防小鼠胰腺切除术后早期肝转移
该研究在小鼠胰腺癌细胞PAN02中比较FUT-175组与对照组的体外侵袭、核因子-κB活化及MMP表达,并在小鼠肝转移模型中评估围术期FUT-175对肝转移和生存的影响。结果显示FUT-175不抑制细胞活力但抑制侵袭,降低核因子-κB活化及MT1-MMP/MMP-14和MMP-2/9水平,体内无病生存和总生存延长,全身给药也可减少转移灶数量。
要点
- FUT-175不抑制PAN02细胞活力,但可抑制细胞侵袭。
- FUT-175降低核因子-κB活化及MT1-MMP/MMP-14、MMP-2/9水平。
- 小鼠模型中围术期FUT-175延长无病生存和总生存,全身给药减少转移灶数量。
核心结论
- 围术期FUT-175治疗可能有助于预防胰腺癌胰腺切除术后早期肝转移。
研究设计与样本
- 体外使用小鼠胰腺癌细胞PAN02比较对照组与FUT-175组的细胞活力、侵袭、核因子-κB信号及MMP表达。
- 体内使用已建立的小鼠肝转移模型评估FUT-175预处理对肝转移、无病生存和总生存的影响,并用磁共振成像评估肝转移灶。
- 另检测全身给予FUT-175的抗转移效果。
主要发现
- FUT-175在治疗24小时及之后不抑制PAN02细胞活力(P > .05)。
- FUT-175组细胞侵袭较对照组受抑制(P < .05)。
- FUT-175组核因子-κB活化、MT1-MMP/MMP-14及MMP-2/9水平低于对照组。
- 体内FUT-175组无病生存和总生存较对照组延长。
- 全身给药也可抑制转移灶数量。
临床怎么用
- 该结果为小鼠模型证据,提示围术期核因子-κB抑制可能成为预防胰腺癌术后早期肝转移的策略。
- 临床转化前需进一步研究FUT-175在人体的安全性、剂量及疗效。
局限性
- 研究仅使用小鼠胰腺癌细胞PAN02和小鼠肝转移模型,结果不能直接外推至人类。
- 原文未报告样本量、具体生存期数值及转移灶数量统计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Liver metastasis is a common problem after pancreatectomy for pancreatic cancer. In pancreatic cancer cells, nuclear factor-κB is activated constitutively. Nuclear factor-κB activates matrix metalloproteinase-2/9, which plays an important role in cancer metastasis. Because the serine protease inhibitor FUT-175 suppresses nuclear factor-κB, we hypothesized that perioperative treatment with FUT-175 for pancreatic cancer may help to prevent liver metastasis. METHODS: We compared in vitro cell viability, cell invasiveness, nuclear factor-κB signaling, and the expression levels of matrix metalloproteinase signals between the control group (C group) and the FUT-175 group (F group) using the murine pancreatic cancer cells PAN02. In addition, we evaluated the in vivo effect of pretreatment with FUT-175 using an established model of liver metastasis in mice. Metastatic liver lesions were assessed with magnetic resonance imaging. Liver recurrence and overall survival were evaluated. Also, the antimetastatic effect of systemic administration of FUT-175 was examined. RESULTS: FUT-175 did not suppress the cell viability of PAN02 cells at or after 24 hours of treatment (P > .05); however, cell invasion was suppressed in the F group compared with the C group (P < .05). The levels of nuclear factor-κB activation, membrane type-1 (MT-1) matrix metalloproteinase (MMP)/matrix metalloproteinase-14 (MMP-14), and matrix metalloproteinase-2/9 (MMP-2/9) were lower in the F group compared with the C group. In vivo, both disease-free and overall survivals were prolonged in the F group compared with the C group. Systemic administration was also effective in suppressing the number of metastases. CONCLUSION: Perioperative treatment with FUT-175 may help to prevent early liver metastasis after pancreatectomy for pancreatic cancer.
引用
- Saito N, Uwagawa T, Hamura R, et al. Prevention of early liver metastasis after pancreatectomy by perioperative administration of a nuclear factor-κB inhibitor in mice. Surgery. 2019. PMID: 31353078. doi:10.1016/j.surg.2019.05.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。